Immune Therapeutics, Inc. Shareholder Update Letter

Immune Therapeutics, Inc. Shareholder Update Letter

ORLANDO, Fla., Nov. 30, 2017 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB: IMUN), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products to alleviate human suffering in HIV/AIDS, cancer, pain, opportunistic infections and autoimmune and inflammatory disease areas today provided the following letter to shareholders:
Dear Shareholder:
We have had a lot of developments since our last Shareholder update. We know many of you have been asking for updates and we are excited to share the most recent news. We apologize for being relatively quiet this past year, but we will now make it a priority to have consistent updates for our shareholders.
We know results will speak for themselves and we have certainly had our challenges, but I am extremely excited and optimistic about our future. Creating and developing the assets that we currently have has taken a considerable amount of time, dedication, effort and a "never give-up" attitude. With many pieces of the puzzle now together, I believe that we are poised to embark on a journey that will transform Immune Therapeutics and propel us to success.

Read More
IMMUNE THERAPEUTICS, INC. APPOINTS JOHN H. ABELES, M.D. AS CHAIRMAN AND CEO OF COMPANY’S SUBSIDIARY, CYTOCOM, INC. AND AS SENIOR ADVISER TO IMMUNE THERAPEUTICS, INC.

IMMUNE THERAPEUTICS, INC. APPOINTS JOHN H. ABELES, M.D. AS CHAIRMAN AND CEO OF COMPANY’S SUBSIDIARY, CYTOCOM, INC. AND AS SENIOR ADVISER TO IMMUNE THERAPEUTICS, INC.

Appointment of Experienced Biotech Industry Veteran and Wall Street Executive to Spearhead Cytocom’s Future Growth and Expansion ORLANDO, Florida, August...

Read More
Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement

Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement

ORLANDO, Fla., April 12, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM, its proprietary formulation of lower-dose naltrexone, today announced, that it has further strengthened its balance sheet by settling an outstanding long-term debt. As a result, the Company has settled the majority of its outstanding convertible long-term debt, putting the Company on firm financial ground to move ahead with its business plan.

Read More
  • 1
  • 2